ClinicalTrials.gg
CompletedNCT01370538NEXT2Updated Apr 11, 2013Results posted

Efficacy of Esomeprazole in Patients With Frequent Heartburn

A Phase 3 interventional study of Esomeprazole in Heartburn, sponsored by AstraZeneca. Completed at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-04-11.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
341
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing esomeprazole in Heartburn — none open to participants now, none under way, none of them phase 3. Esomeprazole · Heartburn.

Enrollment
6th of 19
341 · median 248
Started
2011
with 2 others
Phase 3
3 of 19
none open now
Registered
16th of 19
by date
Lead sponsor
15 of 19
AstraZeneca

Among the 19 studies testing esomeprazole in Heartburn, this one is the 6th largest by enrollment, is one of 3 that started in 2011, is one of 3 in phase 3, and was the 16th registered.

Heartburn

154 studies on the registry are indexed under Heartburn; 12 are open to participants now.

Browse Heartburn studies →

Open to participants now

None of the 19 studies testing esomeprazole in Heartburn is open now. The open studies under Heartburn, anywhere →

About esomeprazole

Esomeprazole: first FDA approval 2001 (NEXIUM), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 8 Heartburn studies recruiting now, 5 set no upper age limit and 3 stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing esomeprazole in Heartburn as a file.
02

Study summary

This study will investigate the efficacy of esomeprazole 20 mg once a day in the treatment of frequent heartburn

03

Conditions studied

  • Heartburn

Browse trials for

Keywords

  • Heartburn
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and non-pregnant ,non-lactating females 18 years or older
  • Experience heartburn at least 2 days a week
  • Having heartburn that has responded to heartburn medication
  • Must discontinue any current heartburn medications

Exclusion criteria

Exclusion Criteria:

  • Having a history of erosive esophagitis verified by endoscopy
  • Having a history of GERD which was diagnosed by a physician
  • Inability to take study medication or complete the study and all study procedures
  • Subjects that have required more than one 14-day course of PPI treatment within the past 4 months
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
341 participants (actual)

Study arms

  • Experimental
    Esomeprazole 20 mg

    Drug: Esomeprazole

  • Placebo comparator
    Placebo

    Drug: Esomeprazole

Interventions

  • Nexium 20 mg administered as 22.3 mg of esomeprasole magnesium hydrate, capsule, oral dose

06

What researchers measure

Primary outcomes

  1. Percentage of Heartburn Free 24 Hour Days During 14 Days of Randomized Treatment

    Time frame: From randomisation to day 14

Secondary outcomes

  1. Number of Subjects Reporting Heartburn 2 Days or Less During the 14 Days Randomized Treatment Period

    Treatment period is considered to be both weeks 1 and 2 between V3 and V4.

    Time frame: From randomisation to the day 14

  2. Comparison of Number of Subjects With 0, 1, 2, 3 or 4 Days With no Heartburn Over Days 1 to 4 Between Esomeprazole 20 mg and Placebo

    The first 4 consecutive days subjects were on randomized treatment, between V3 and V4.

    Time frame: From randomisation to day 14

  3. Number of Subjects With Heartburn 1 Day or Less During the Final Week, Second Week, First Week of Treatment

    There were three separate 7 day time periods during the treatment period; The first week (days 1-7), the second week (days 8-14), and the last 7 consecutive days (last day subject reported and the prior 6). For a given subject, the second week and last 7 consecutive days are the same if the subject has recorded measurements for the entire 14 day treatment period. However, for subjects reporting anything less than 14 days the two will not be identical. For all three 7 day time periods, days when a subject did not call in (i.e., missing values) were imputed as a day with heartburn.

    Time frame: From randomisation to day 14

07

Results

Posted Apr 11, 2013

Participant flow

From total of 526 screened subjects, 341 subjects were randomised. From 341 subjects 170 and 171 were allocated to Esomeprazole and Placebo respectively.

Participant flow — Overall Study
MilestoneEsomeprazolePlacebo
Started170171
Patients who received treatment165161
Patients who completed treatment151152
Completed151152
Not completed1919
Withdrew: Voluntary discontinuation by subject32
Withdrew: Eligibility criteria not fulfilled01
Withdrew: Adverse event10
Withdrew: Protocol violation85
Withdrew: Development of study specific withdrawal11
Withdrew: Lost to follow up610

Outcome measures

PrimaryPercentage of Heartburn Free 24 Hour Days During 14 Days of Randomized Treatment
Time frame:
From randomisation to day 14
Reported as:
Mean · Percentage of heartburn free days
Percentage of Heartburn Free 24 Hour Days During 14 Days of Randomized Treatment
Percentage of heartburn free daysEsomeprazolePlacebo
Percentage of Heartburn Free 24 Hour Days During 14 Days of Randomized Treatment46.79 ± 33.3230.93 ± 28.86
SecondaryNumber of Subjects Reporting Heartburn 2 Days or Less During the 14 Days Randomized Treatment Period

Treatment period is considered to be both weeks 1 and 2 between V3 and V4.

Time frame:
From randomisation to the day 14
Reported as:
Number · Participants
Number of Subjects Reporting Heartburn 2 Days or Less During the 14 Days Randomized Treatment Period
ParticipantsEsomeprazolePlacebo
Number of Subjects Reporting Heartburn 2 Days or Less During the 14 Days Randomized Treatment Period272
SecondaryComparison of Number of Subjects With 0, 1, 2, 3 or 4 Days With no Heartburn Over Days 1 to 4 Between Esomeprazole 20 mg and Placebo

The first 4 consecutive days subjects were on randomized treatment, between V3 and V4.

Time frame:
From randomisation to day 14
Reported as:
Number · Participants
Comparison of Number of Subjects With 0, 1, 2, 3 or 4 Days With no Heartburn Over Days 1 to 4 Between Esomeprazole 20 mg and Placebo
ParticipantsEsomeprazolePlacebo
Zero days5577
One day3234
Two days2229
Three days3716
Four days162
SecondaryNumber of Subjects With Heartburn 1 Day or Less During the Final Week, Second Week, First Week of Treatment

There were three separate 7 day time periods during the treatment period; The first week (days 1-7), the second week (days 8-14), and the last 7 consecutive days (last day subject reported and the prior 6). For a given subject, the second week and last 7 consecutive days are the same if the subject has recorded measurements for the entire 14 day treatment period. However, for subjects reporting anything less than 14 days the two will not be identical. For all three 7 day time periods, days when a subject did not call in (i.e., missing values) were imputed as a day with heartburn.

Time frame:
From randomisation to day 14
Reported as:
Number · Participants
Number of Subjects With Heartburn 1 Day or Less During the Final Week, Second Week, First Week of Treatment
ParticipantsEsomeprazolePlacebo
Last 7 consecutive days4017
Second 7 calendar days3813
First 7 calendar days327
PrimaryPercentage of Heartburn Free 24 Hour Days During 14 Days of Randomized Treatment
Time frame:
From randomisation to day 14
Reported as:
Mean · Percentage of heartburn free days
Percentage of Heartburn Free 24 Hour Days During 14 Days of Randomized Treatment
Percentage of heartburn free daysEsomeprazolePlacebo
Percentage of Heartburn Free 24 Hour Days During 14 Days of Randomized Treatment47.82 ± 33.2328.83 ± 31.22

Adverse events

Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Esomeprazole—0/162 (0%)18/162 (11.1%)
Placebo—0/158 (0%)15/158 (9.5%)
Most frequent other events
Showing 10 of 18
Most frequent other events
EventEsomeprazolePlacebo
NauseaGastrointestinal disorders5/1624/158
ConstipationGastrointestinal disorders4/1620/158
DiarrhoeaGastrointestinal disorders4/1623/158
PainGeneral disorders0/1623/158
MyalgiaMusculoskeletal and connective tissue disorders3/1620/158
Nasal congestionRespiratory, thoracic and mediastinal disorders3/1621/158
Dry mouthGastrointestinal disorders1/1622/158
VomitingGastrointestinal disorders0/1622/158
PyrexiaGeneral disorders0/1622/158
NasopharyngitisInfections and infestations2/1622/158

Baseline characteristics

Age Continuous
Age Continuous(Years)EsomeprazolePlaceboTotal
All41.6 ± 14.042.8 ± 13.242.2 ± 13.6
Sex: Female, Male
Sex: Female, Male(Participants)EsomeprazolePlaceboTotal
Female9187178
Male7984163
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)EsomeprazolePlaceboTotal
WHITE111120231
BLACK OR AFRICAN AMERICAN5250102
NATIVE HAWAIIAN/PACIFIC ISLANDER101
AMERICAN INDIAN/ALASKA NATIVE303
OTHER314
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)EsomeprazolePlaceboTotal
HISPANIC OR LATINO242549
NOT HISPANIC OR LATINO5546101
NOT REPORTED91100191
08

Study locations

10 sites
  • Research site
    Mobile, Alabama, United States
  • Research site
    San Francisco, California, United States
  • Research site
    Westlake Village, California, United States
  • Research site
    Lexington, Kentucky, United States
  • Research site
    Rochester, New York, United States
  • Research site
    Dakota Dunes, South Dakota, United States
  • Research site
    Nashville, Tennessee, United States
  • Research site
    Austin, Texas, United States
  • Research site
    San Angelo, Texas, United States
  • Research site
    West Jordan, Utah, United States
09

References and documents

Publications

  • Peura D, Le Moigne A, Wassel H, Pollack C. Analysis of the symptom response to esomeprazole 20 mg over days 1-4 of a 14-day course of treatment for frequent heartburn: results of two randomised controlled trials. BMJ Open Gastroenterol. 2019 Jun 21;6(1):e000278. doi: 10.1136/bmjgast-2019-000278. eCollection 2019. PubMed 31297231 ↗
  • Peura DA, Le Moigne A, Wassel H, Pollack C. Sustained efficacy following resolution of frequent heartburn with an over-the-counter regimen of esomeprazole 20 mg or placebo for 14 days: two randomized trials. BMC Gastroenterol. 2018 May 22;18(1):69. doi: 10.1186/s12876-018-0790-2. PubMed 29788903 ↗
  • Peura D, Le Moigne A, Pollack C, Nagy P, Lind T. A 14-day regimen of esomeprazole 20 mg/day for frequent heartburn: durability of effects, symptomatic rebound, and treatment satisfaction. Postgrad Med. 2016 Aug;128(6):577-83. doi: 10.1080/00325481.2016.1203236. Epub 2016 Jul 4. PubMed 27331882 ↗
  • Peura DA, Traxler B, Kocun C, Lind T. Esomeprazole treatment of frequent heartburn: two randomized, double-blind, placebo-controlled trials. Postgrad Med. 2014 Jul;126(4):33-41. doi: 10.3810/pgm.2014.07.2781. PubMed 25141241 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2011, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2013, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2011
First posted
Jun 10, 2011
Start
Aug 2011
Primary completionActual
Oct 2011
CompletionActual
Oct 2011
Results first posted
Apr 11, 2013
Last update
Apr 11, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01370538
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jun 10, 2011
Start date
Aug 2011
Primary completion
Oct 2011
Completion
Oct 2011
Results posted
Apr 11, 2013
Last update
Apr 11, 2013

Study contacts

Tore Lind, MD
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esomeprazole

Start the discussion